Categories: Eye diseases, Immune diseases, Infectious diseases, Rare diseases, Skin diseases

Aliases & Classifications for Onchocerciasis

MalaCards integrated aliases for Onchocerciasis:

Name: Onchocerciasis 12 73 20 58 54 3 44 15 17 70 32
River Blindness 20 3
Infection by Onchocerca Volvulus 12
Onchocerca Volvulus Infection 12
Onchocerciasis, Ocular 70
Robles' Disease 20
Volvulosis 12


Orphanet epidemiological data:

Inheritance: Not applicable; Age of onset: All ages;


Orphanet: 58  
Rare infectious diseases

External Ids:

Disease Ontology 12 DOID:11678
ICD9CM 34 125.3
MeSH 44 D009855
NCIt 50 C34861
SNOMED-CT 67 38539003
ICD10 32 B73
MESH via Orphanet 45 D009855 D015827
ICD10 via Orphanet 33 B73
UMLS via Orphanet 71 C0029001 C0029002
Orphanet 58 ORPHA2737
UMLS 70 C0029001 C0029002

Summaries for Onchocerciasis

GARD : 20 Onchocerciasis is a rare tropical parasitic disease transmitted by a black fly. Infection by the parasite can cause eye and skin problems. In humans, the parasitic worms live under the skin (subcutaneous nodules) and produce larvae (microfilariae). The larvae are found throughout the body, but especially in the skin and eyes. Repeated bites by infected flies increase the number of adult worms and larvae. Chronic skin onchocerciasis (onchodermatitis) causes itching, a rash with small pimples (papular rash), scarring, and thickened, leathery skin (lichenification). Other symptoms may develop over time and might include saggy skin (such as ''hanging groin''), patchy areas of much lighter colored skin (leopard skin), ichthyosis -like lesions (''lizard skin''), darkening of the skin, and very severe itching. The eye infection is known as river blindness because the blackfly carrying the parasite lives near fast-flowing waters. Symptoms of an eye infection may include itchy eyes, red eyes, and sensitivity to light ( photophobia ). In some cases, the larvae may infect the optic nerve. As the common name suggests, infection of the eye by onchocerciasis can lead to vision loss and eventually blindness. The disease is caused by the parasitic worm Onchocerca volvulus and is transmitted by the bite of an infected black fly. About 90% of the cases occur in Africa. Treatment aims to remove the larvae (microfilariae), to improve symptoms, to prevent progression of eye lesions, and to stop the parasite from being passed back to black flies so other people do not become infected. Medications include an anti-parasitic known as ivermectin, antibiotics such as rifampin, azithromycin, and doxycycline, and, another recently approved anti-parasitic drug, Moxidectin.

MalaCards based summary : Onchocerciasis, also known as river blindness, is related to loiasis and filariasis. An important gene associated with Onchocerciasis is IL5 (Interleukin 5), and among its related pathways/superpathways are PEDF Induced Signaling and Akt Signaling. The drugs Anticonvulsants and Albendazole have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and neutrophil, and related phenotypes are hematopoietic system and immune system

Disease Ontology : 12 A filariasis that involves parasitic infection caused by the nematode Onchocerca volvulus, which is transmitted to humans through the bite of a blackfly of the genus Simulium. The worms spread throughout the body and, when they die, cause intense itching and a strong immune system response that can destroy nearby tissue. The symptoms include pruritus, dermatitis, blindness, onchocercomata (subcutaneous nodules), and lymphadenopathy.

CDC : 3 Onchocerciasis, or River Blindness, is a neglected tropical disease (NTD) caused by the parasitic worm Onchocerca volvulus. It is transmitted through repeated bites by blackflies of the genus Simulium. The disease is called River Blindness because the blackfly that transmits the infection lives and breeds near fast-flowing streams and rivers and the infection can result in blindness. In addition to visual impairment or blindness, onchocerciasis causes skin disease, including nodules under the skin or debilitating itching. Worldwide onchocerciasis is second only to trachoma as an infectious cause of blindness.

Wikipedia : 73 Onchocerciasis, also known as river blindness, is a disease caused by infection with the parasitic worm... more...

Related Diseases for Onchocerciasis

Diseases related to Onchocerciasis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 379)
# Related Disease Score Top Affiliating Genes
1 loiasis 31.7 IL5 IL4 IL13 EPX CCL11
2 filariasis 31.4 IL5 IL2 IGHE CCL5
3 filarial elephantiasis 31.3 IL5 IL4 IL2 IL13
4 sclerosing keratitis 31.2 RBP3 IL2
5 uveitis 30.8 RBP3 IL4 IL2 CCL11
6 cysticercosis 30.7 IL5 IL4 IGHE
7 elephantiasis 30.5 RNASE3 IL5 IL4 IL13 ELANE
8 schistosomiasis 30.5 RNASE3 IL5 IL4 IL2 IL13 IGHE
9 cytokine deficiency 30.4 IL5 IL13
10 tetanus 30.2 IL5 IL4 IL2 IL13 CSF2
11 wells syndrome 30.2 RNASE3 IL5 IL2
12 leprosy 3 30.2 IL5 IL4 IL2 IL13 HLA-DQA1 CSF2
13 cellulitis 30.2 RNASE3 IL5 CSF2
14 strongyloidiasis 30.1 IL5 IL4 IL13 IGHE CCL11
15 urinary schistosomiasis 30.0 RNASE3 IL5 IL4 IL13 IGHE EPX
16 ige responsiveness, atopic 30.0 RNASE3 IL5 IL4 IL13 IGHE
17 ascaris lumbricoides infection 30.0 SERPINA3 IL5 IL13
18 stomatitis 30.0 IL4 IL2 CSF2
19 intestinal schistosomiasis 29.9 IL5 IL4 IL2 IL13
20 conjunctivitis 29.8 RNASE3 IL5 IL4 IL2 IL13 IGHE
21 toxocariasis 29.8 RNASE3 IL5 IL4 IL13 IGHE
22 posterior uveitis 29.7 RBP3 IL5 IL4 IL2 IL13
23 chagas disease 29.7 IL4 IL2 CCL5 CALR
24 severe combined immunodeficiency 29.7 IL4 IL2 IL13 CSF2
25 hypereosinophilic syndrome 29.7 RNASE3 IL5 IL4 IL2 IL13 IGHE
26 leishmaniasis 29.6 IL5 IL4 IL2 IL13 HLA-DQA1
27 rubella 29.5 IL5 IL4 IL2 HLA-DQA1 CALR
28 allergic conjunctivitis 29.3 RNASE3 IL5 IL4 IL2 IL13 IGHE
29 keratoconjunctivitis 29.3 RNASE3 IL5 IL4 IL2 IL13 CCL5
30 eosinophilic pneumonia 29.2 RNASE3 IL5 IL4 IL13 CSF2 CCL5
31 skin disease 29.2 SERPINA3 RNASE3 IL5 IL4 IL2 IL13
32 hyper ige syndrome 29.1 RNASE3 IL4 IL13 IGHE CSF2 CCL7
33 dermatitis 29.1 RNASE3 IL5 IL4 IL2 IL13 IGHE
34 sarcoidosis 1 29.1 SERPINA3 IL2 IL13 CCL5 CCL11
35 eye disease 29.0 SERPINA3 RBP3 LMOD1 IL5 IL4 IL2
36 allergic disease 29.0 RNASE3 IL5 IL4 IL2 IL13 IGHE
37 parasitic helminthiasis infectious disease 28.7 SERPINA3 RNASE3 IL5 IL4 IL2 IL13
38 pulmonary eosinophilia 28.7 RNASE3 IL5 IL4 IL13 EPX CSF2
39 immune deficiency disease 28.4 SERPINA3 IL4 IL2 IL13 CSF2 CCL7
40 autoimmune disease 28.2 RBP3 IL5 IL4 IL2 IL13 HLA-DQA1
41 dermatitis, atopic 27.4 SERPINA3 RNASE3 IL5 IL4 IL2 IL13
42 malaria 26.9 SERPINA3 RNASE3 LTF IL5 IL4 IL2
43 volvulus of midgut 11.1
44 yemenite deaf-blind hypopigmentation syndrome 10.9
45 hr44 antigen 10.9
46 epilepsy 10.6
47 keratitis, hereditary 10.6
48 iridocyclitis 10.4
49 chorioretinitis 10.4
50 1-chloro-2,4-dinitrobenzene allergic contact dermatitis 10.4 IL4 IL2

Graphical network of the top 20 diseases related to Onchocerciasis:

Diseases related to Onchocerciasis

Symptoms & Phenotypes for Onchocerciasis

MGI Mouse Phenotypes related to Onchocerciasis:

# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 CCL11 CCL5 CSF2 ELANE EPX FCER2
2 immune system MP:0005387 9.4 CCL11 CCL5 CSF2 ELANE EPX FCER2

Drugs & Therapeutics for Onchocerciasis

Drugs for Onchocerciasis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 29)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Anticonvulsants Phase 4
Albendazole Approved, Vet_approved Phase 3 54965-21-8 2082
Ivermectin Approved, Investigational, Vet_approved Phase 3 70288-86-7 6474909
4 Tubulin Modulators Phase 3
5 Antimitotic Agents Phase 3
6 Antiprotozoal Agents Phase 3
7 Vitamins Phase 3
8 Milbemycin Phase 3
9 Antiparasitic Agents Phase 3
10 Anti-Infective Agents Phase 3
11 Anthelmintics Phase 3
Rifampicin Approved Phase 2 13292-46-1 5381226 5458213
Azithromycin Approved Phase 2 83905-01-5 447043 55185
Diethylcarbamazine Approved, Investigational, Vet_approved Phase 2 90-89-1 3052
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 2 14769-73-4 26879
16 Antibiotics, Antitubercular Phase 2
17 Antitubercular Agents Phase 2
18 Anti-Bacterial Agents Phase 2
Sodium citrate Approved, Investigational 68-04-2
Piperazine Approved, Vet_approved 110-85-0 4837
Mebendazole Approved, Vet_approved 31431-39-7 4030
Citric acid Approved, Nutraceutical, Vet_approved 77-92-9 311
23 Citrate
24 Chelating Agents
25 Anticoagulants
26 DMP 777 157341-41-8
27 Piperazine citrate
28 Calcium, Dietary
Calcium Nutraceutical 7440-70-2 271

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Ivermectin Treatment in Patients With Onchocerciasis-associated Epilepsy: A Randomized Clinical Trial Completed NCT03052998 Phase 4 Ivermectin
2 OAETREAT Extra Ivermectin Treatment of Persons With Onchocerciasis-associated Epilepsy: a Completed NCT03852303 Phase 4 ivermectin
3 A Single-Dose, Ivermectin-Controlled, Double-Blind, Efficacy, Safety And Tolerability Study Of Orally Administered Moxidectin In Subjects Infected With Onchocerca Volvulus Completed NCT00790998 Phase 3 Moxidectin;Ivermectin
4 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis Completed NCT03238131 Phase 3 Ivermectin;Albendazole
5 Comparison of Ivermectin Alone With Albendazole (ALB) Plus Ivermectin (IVM) in Their Efficacy Against Onchocerciasis in the Volta Region, Ghana. Completed NCT02078024 Phase 3 IVM plus ALB;IVM
6 A Randomized, Double Blind, Parallel Trial in the Democratic Republic of Congo (DRC) Comparing the Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Treatment of Onchocerciasis Not yet recruiting NCT03876262 Phase 3 Moxidectin;Ivermectin
7 A Randomized, Double Blind, Parallel Group Clinical Trial to Evaluate the Safety of Moxidectin Compared With Ivermectin in Individuals Living in Onchocerciasis Endemic Areas Not yet recruiting NCT04311671 Phase 3 Moxidectin;Ivermectin
8 A Randomized, Single-Ascending Dose, Ivermectin-Controlled, Double-Blind, Safety, Tolerability, Pharmacokinetic, and Efficacy Study Of Orally Administered Moxidectin In Subjects With Onchocerca Volvulus Infection Completed NCT00300768 Phase 2 2 mg moxidectin;ivermectin 150 mcg/kg;4 mg moxidectin;8 mg moxidectin
9 Trial of Rifampin and Azithromycin for Treatment of Endosymbiotic Bacteria (Wolbachia) in Onchocerca Volvulus in Guatemala Completed NCT00127504 Phase 2 Rifampin;Azithromycin
10 Safety and Efficacy of Combination Therapy With Ivermectin, Diethylcarbamazine, and Albendazole (IDA) for Individuals With Onchocerciasis Enrolling by invitation NCT04188301 Phase 2 IVM w/ ALB;Single dose of IDA;Three daily doses of IDA
11 Randomized Clinical Trial, Double-blind, Single-dose Drug and Escalating Infection Intensities, Evaluating the Safety and Efficacy of Moxidectin 2 mg, Ivermectin-controlled, in Loa Loa Microfilaremic Patients Not yet recruiting NCT04049851 Phase 2 Moxidectin 2 MG Oral Tablet;Ivermectin 3Mg Tab;Placebo oral tablet
12 Randomized Clinical Trial, Double-blind, Dose-escalating of Drug Intensities, Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients Not yet recruiting NCT04049630 Phase 2 LEV 1 mg/kg;LEV 1,5 mg/kg;Placebo
13 A Single-Center, Open-Label, Single-Dose Study To Assess The Pharmacokinetics, Safety, And Tolerability Of Moxidectin In Subjects Aged 4 To 11 Years ( >=12 kg) With Or Without Onchocerca Volvulus Infection Withdrawn NCT01035619 Phase 2 moxidectin
14 An Open-label Study of the Pharmacokinetics and Safety of a Single Dose of Moxidectin Per Oral in Subjects Aged 4 to 17 Years With (or at Risk of) Onchocerciasis to Identify an Optimal Dose for Treatment of Children 4 to 11 Years Not yet recruiting NCT03962062 Phase 1 Moxidectin
15 Clinical Features and Potential Etiology of Epilepsy and Nodding Syndrome in the Mahenge Area, Ulanga District Unknown status NCT03653975
16 Microfilarial Clearance From the Eye and Ocular Changes Associated With Ivermectin Treatment in Individuals With Onchocerciasis Completed NCT03517462 Ivermectin 3Mg Tab
17 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis Completed NCT01905423 Albendazole (annual);Diethylcarbamazine (annual);Albendazole (semiannual);Diethylcarbamazine (semiannual)
18 Determination of the Prevalence of LF Infection in Districts Not Included in LF Control Activities and of the Basis for Integrated Implementation of LF - Onchocerciasis Elimination Strategies in Potentially Co-endemic Areas Completed NCT03131401
19 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Ivory Coast Completed NCT02032043 Annual versus Semiannual Albendazole plus Ivermectin MDA
20 Host Response to Infection and Treatment in the Filarial Diseases of Humans Recruiting NCT00001230
21 Optimization of Mass Drug Administration With Existing Drug Regimens for Lymphatic Filariasis and Onchocerciasis for Liberia Enrolling by invitation NCT01905436 Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration
22 Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa Not yet recruiting NCT04035174

Search NIH Clinical Center for Onchocerciasis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Cochrane evidence based reviews: onchocerciasis

Genetic Tests for Onchocerciasis

Anatomical Context for Onchocerciasis

MalaCards organs/tissues related to Onchocerciasis:

Skin, Eye, Neutrophil, T Cells, Breast, Brain, Salivary Gland

Publications for Onchocerciasis

Articles related to Onchocerciasis:

(show top 50) (show all 3810)
# Title Authors PMID Year
Onchocerca volvulus-specific antibody and cytokine responses in onchocerciasis patients after 16 years of repeated ivermectin therapy. 61 54
17302900 2007
Genetic polymorphism of the beta-tubulin gene of Onchocerca volvulus in ivermectin naïve patients from Cameroon, and its relationship with fertility of the worms. 54 61
16197589 2006
Antigen-specific T regulatory-1 cells are associated with immunosuppression in a chronic helminth infection (onchocerciasis). 54 61
12443893 2002
Eosinophil granule proteins in serum and urine of patients with helminth infections and atopic dermatitis. 54 61
11169280 2000
Pathophysiological roles of calreticulin in autoimmune disease. 61 54
10320638 1999
Eosinophils, eosinophil cationic protein and eosinophil-derived neurotoxin in serum and urine of patients with onchocerciasis coinfected with intestinal nematodes and in urinary schistosomiasis. 61 54
10206116 1999
Characterization of human immune responses to the cytosolic superoxide dismutase and glutathione S-transferase from Onchocerca volvulus. 54 61
9294549 1997
The diverse expression of immunity in humans at distinct states of Onchocerca volvulus infection. 61 54
9176114 1997
Serum levels of eosinophil cationic protein, eosinophil-derived neurotoxin and myeloperoxidase in infections with filariae and schistosomes. 54 61
9025985 1996
Elevations in granulocyte-macrophage colony-stimulating factor and interleukin-5 levels precede posttreatment eosinophilia in onchocerciasis. 54 61
8627086 1996
A 16mer peptide of the human autoantigen calreticulin is a most prominent HLA-DR4Dw4-associated self-peptide. 61 54
7836063 1994
Epitopes of the Onchocerca volvulus RAL1 antigen, a member of the calreticulin family of proteins, recognized by sera from patients with onchocerciasis. 61 54
7520419 1994
Regulation of IL-5 in onchocerciasis. A critical role for IL-2. 61 54
8099937 1993
Calreticulin synthetic peptide analogues: anti-peptide antibodies in autoimmune rheumatic diseases. 61 54
7680295 1993
Serological cross-reactivity between a human Ro/SS-A autoantigen (calreticulin) and the lambda Ral-1 antigen of Onchocerca volvulus. 61 54
1602002 1992
Interleukin-5 and the posttreatment eosinophilia in patients with onchocerciasis. 61 54
1918387 1991
Analysis of aqueous humour in ocular onchocerciasis. 61 54
2036808 1991
Cell-mediated immunity against human retinal extract, S-antigen, and interphotoreceptor retinoid binding protein in onchocercal chorioretinopathy. 61 54
2210999 1990
Humoral autoimmune response against S-antigen and IRBP in ocular onchocerciasis. 54 61
2365568 1990
Humoral and cell-mediated immune response against human retinal antigens in relation to ocular onchocerciasis. 54 61
2378211 1990
Genome editing as control tool for filarial infections. 61
33581654 2021
Attendee awareness about preventive chemotherapy neglected tropical diseases (PC-NTD) control during the first world neglected tropical diseases day in Ekiti State, Nigeria. 61
33780462 2021
Community-directed distributors-The "foot soldiers" in the fight to control and eliminate neglected tropical diseases. 61
33661903 2021
Cytokines and Onchocerciasis-Associated Epilepsy, a Pilot Study and Review of the Literature. 61
33799934 2021
Socio-cultural factors in onchocerciasis control: a study of rural Southeast Nigeria. 61
33746381 2021
Community perceptions and attitudes regarding epilepsy and disease cost after implementation of a community-based epilepsy treatment program in onchocerciasis-endemic communities in the Democratic Republic of Congo. 61
33515932 2021
Onchocerciasis Prevalence among Persons with Epilepsy in an Onchocerciasis Hypo-Endemic Area in the Democratic Republic of Congo: A Cross-Sectional Study. 61
33805016 2021
Pioneering research on American onchocerciasis: a tribute to Leon Goldman, MD. 61
32686146 2021
Efficacy and safety of ascending doses of moxidectin against Strongyloides stercoralis infections in adults: a randomised, parallel-group, single-blinded, placebo-controlled, dose-ranging, phase 2a trial. 61
33798487 2021
Safety, tolerability and pharmacokinetics of emodepside, a potential novel treatment for onchocerciasis (river blindness), in healthy male subjects. 61
33759250 2021
Morinda lucida Benth (Rubiaceae): A review of its ethnomedicine, phytochemistry and pharmacology. 61
33753141 2021
Complex emergencies and the control and elimination of neglected tropical diseases in Africa: developing a practical approach for implementing safe and effective mapping and intervention strategies. 61
33789715 2021
Nodding syndrome research revisited. 61
33556614 2021
The impact of ivermectin on onchocerciasis in villages co-endemic for lymphatic filariasis in an area of onchocerciasis recrudescence in Burkina Faso. 61
33647010 2021
Potential Parasitic Causes of Epilepsy in an Onchocerciasis Endemic Area in the Ituri Province, Democratic Republic of Congo. 61
33803565 2021
What does the COVID-19 pandemic mean for the next decade of onchocerciasis control and elimination? 61
33515042 2021
Progress towards onchocerciasis elimination in Côte d'Ivoire: A geospatial modelling study. 61
33566805 2021
In pursuit of a cure: The plural therapeutic landscape of onchocerciasis-associated epilepsy in Cameroon - A mixed methods study. 61
33621233 2021
The elusive elimination of river blindness. 61
33515523 2021
The Eagle effect in the Wolbachia-worm symbiosis. 61
33627171 2021
Mapping the burden of onchocercal skin disease. 61
32302410 2021
Onchocerciasis in tropical neurology: A scoping review. 61
33493958 2021
Human filariasis-contributions of the Litomosoides sigmodontis and Acanthocheilonema viteae animal model. 61
33547508 2021
Infectious diseases among Ethiopian immigrants in Israel: a descriptive literature review. 61
33624575 2021
Drugs that target early stages of Onchocerca volvulus: A revisited means to facilitate the elimination goals for onchocerciasis. 61
33600426 2021
Neuropathological Changes in Nakalanga Syndrome-A Case Report. 61
33498763 2021
Micro-CT imaging of Onchocerca infection of Simulium damnosum s.l. blackflies and comparison of the peritrophic membrane thickness of forest and savannah flies. 61
33480060 2021
Computational Design and Preliminary Serological Analysis of a Novel Multi-Epitope Vaccine Candidate against Onchocerciasis and Related Filarial Diseases. 61
33494344 2021
Response to: 'Nodding syndrome, many questions remain but we can prevent it by eliminating onchocerciasis'. 61
33502386 2021
Nodding syndrome, many questions remain but we can prevent it by eliminating onchocerciasis. 61
33502388 2021

Variations for Onchocerciasis

Expression for Onchocerciasis

Search GEO for disease gene expression data for Onchocerciasis.

Pathways for Onchocerciasis

Pathways related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 32)
# Super pathways Score Top Affiliating Genes
Show member pathways
13.62 IL5 IL4 IL2 IL13 FCER2 CSF2
Show member pathways
13.36 IL5 IL4 IL2 IL13 CSF2 CCL7
Show member pathways
Show member pathways
13.25 IL5 IL4 IL2 IL13 CSF2 CCL7
Show member pathways
Show member pathways
Show member pathways
12.65 RNASE3 IL5 IL4 IL2 IL13 HLA-DQA1
Show member pathways
12.56 IL5 IL4 IL2 IL13 HLA-DQA1
Show member pathways
12.55 IL5 IL4 IL13 IGHE CSF2
Show member pathways
12.37 IL5 IL4 IL2 IL13 CSF2
Show member pathways
12.33 IL4 IGHE FCER2 CCL11
Show member pathways
12.32 IL5 IL4 IL13 CSF2 CCL7 CCL11
13 12.28 IL2 HLA-DQA1 CSF2 CALR
Show member pathways
12.27 IL2 CCL7 CCL5 CCL11
Show member pathways
16 11.99 IL4 IL13 IGHE FCER2 CCL11
17 11.96 IL5 IL4 IL2 CSF2
18 11.92 IL5 IL4 HLA-DQA1 FCER2 CSF2
19 11.8 HLA-DQA1 CSF2 CCL5
20 11.77 IL5 IL4 IL2 IL13
21 11.77 IL5 IL4 IL2 IL13 CSF2
Show member pathways
11.74 IL5 IL4 IL2 CSF2
23 11.6 IL5 IL4 IGHE FCER2 CCL11
24 11.46 IL4 IL13 FCER2 CSF2 CCL5
25 11.38 IL5 IL4 IL2 IL13 CCL11
26 11.3 IL5 IL4 IL2
27 11.28 IL5 IL4 IL13
28 11.23 IL5 IL4 IL13 CSF2 CCL5 CCL11
29 11.19 IL5 IL4 IL2 IL13
30 11.02 IL5 IL4 IL2 IL13 CSF2
31 10.94 IL5 IL4 IL2 IL13 CSF2 CCL7
32 10.8 IL5 IL4 IL13

GO Terms for Onchocerciasis

Cellular components related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.83 SERPINA3 RNASE3 RBP3 LTF IL5 IL4
2 extracellular region GO:0005576 9.55 SERPINA3 RNASE3 RBP3 LTF IL5 IL4
3 azurophil granule lumen GO:0035578 9.33 SERPINA3 RNASE3 ELANE

Biological processes related to Onchocerciasis according to GeneCards Suite gene sharing:

(show all 33)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 10.04 IL5 IL4 IL2 CSF2 CALR
2 MAPK cascade GO:0000165 9.96 IL5 IL2 CSF2 CCL5
3 neutrophil degranulation GO:0043312 9.95 SERPINA3 RNASE3 LTF EPX ELANE DSG1
4 positive regulation of cell migration GO:0030335 9.94 IL4 CCL7 CCL5 CCL11
5 inflammatory response GO:0006954 9.91 SERPINA3 IL5 IL13 CCL7 CCL5 CCL11
6 defense response to bacterium GO:0042742 9.89 RNASE3 LTF IGHE EPX ELANE
7 chemotaxis GO:0006935 9.87 RNASE3 CCL7 CCL5 CCL11
8 negative regulation of inflammatory response GO:0050728 9.85 IL4 IL2 IL13 ELANE
9 cellular response to interferon-gamma GO:0071346 9.83 CCL7 CCL5 CCL11
10 cellular response to interleukin-1 GO:0071347 9.81 CCL7 CCL5 CCL11
11 neutrophil chemotaxis GO:0030593 9.8 CCL7 CCL5 CCL11
12 chemokine-mediated signaling pathway GO:0070098 9.8 CCL7 CCL5 CCL11
13 positive regulation of T cell proliferation GO:0042102 9.77 IL4 IL2 CCL5
14 positive regulation of smooth muscle cell proliferation GO:0048661 9.77 IL13 ELANE CCL5
15 antimicrobial humoral response GO:0019730 9.76 RNASE3 LTF ELANE
16 monocyte chemotaxis GO:0002548 9.73 CCL7 CCL5 CCL11
17 lymphocyte chemotaxis GO:0048247 9.71 CCL7 CCL5 CCL11
18 innate immune response in mucosa GO:0002227 9.69 RNASE3 LTF IL4
19 dendritic cell differentiation GO:0097028 9.66 IL4 CSF2
20 cellular calcium ion homeostasis GO:0006874 9.65 ELANE CCL7 CCL5 CCL11 CALR
21 immune response GO:0006955 9.65 IL5 IL4 IL2 IL13 IGHE HLA-DQA1
22 positive regulation of podosome assembly GO:0071803 9.63 IL5 CSF2
23 positive regulation of immunoglobulin production GO:0002639 9.63 IL5 IL2 IL13
24 negative regulation of T-helper 17 cell differentiation GO:2000320 9.62 IL4 IL2
25 positive regulation of B cell proliferation GO:0030890 9.62 IL5 IL4 IL2 IL13
26 positive regulation of isotype switching to IgG isotypes GO:0048304 9.61 IL4 IL2
27 positive regulation of mast cell degranulation GO:0043306 9.61 IL4 IL13
28 positive regulation of natural killer cell chemotaxis GO:2000503 9.58 CCL7 CCL5
29 eosinophil chemotaxis GO:0048245 9.58 CCL7 CCL5 CCL11
30 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.55 IL4 IL2 IL13 CSF2 CCL5
31 macrophage activation GO:0042116 9.54 IL4 IL13 CSF2
32 negative regulation of complement-dependent cytotoxicity GO:1903660 9.52 IL4 IL13
33 cytokine-mediated signaling pathway GO:0019221 9.28 IL5 IL4 IL2 IL13 IGHE FCER2

Molecular functions related to Onchocerciasis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.46 IL5 IL4 IL2 CSF2
2 chemokine activity GO:0008009 9.43 CCL7 CCL5 CCL11
3 CCR1 chemokine receptor binding GO:0031726 9.32 CCL7 CCL5
4 cytokine activity GO:0005125 9.23 IL5 IL4 IL2 IL13 CSF2 CCL7
5 CCR chemokine receptor binding GO:0048020 9.13 CCL7 CCL5 CCL11

Sources for Onchocerciasis

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
69 Tocris
71 UMLS via Orphanet
Loading form....